by Brandon Tudor | Mar 5, 2025 | Uncategorized
Great video from the Liver Education Advocates event (featuring Gina Madison) in Pittsburgh on March 2, 2025, where folks received a liver scan via the Mindray Hepatus 6. SOURCE: WTAE Hepatus 6 Summary:A new era for noninvasive diagnosis of liver disease with a wide...
by Brandon Tudor | Mar 4, 2025 | Uncategorized
In the 02/25/25 article “MASH Drives Increasing Global Incidence of Cirrhosis, Chronic Liver Diseases” in HCP Live, the conclusion is that focused efforts targeted at the metabolic risk factors to curb the rising incidence of MASH, increasing linkage to...
by Brandon Tudor | Mar 2, 2025 | Uncategorized
From the AJMC Journal 02/27/2025: “At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a statistically significant 6.7 kPa reduction in liver stiffness from baseline.” Per the article by Rose...
by Brandon Tudor | Feb 26, 2025 | Uncategorized
“Our study…demonstrate[s] an increased risk of HF in MASLD patients and suggests individuals with MASLD and a high metabolic burden should be vigilant about the potential development of HF.”Conclusion from the 08 January 2025 study published in The...
by Brandon Tudor | Feb 14, 2025 | Uncategorized
We joined the AASLD, and will be at this event in Las Vegas in late February/early March of 2025, and I’d like to meet with attendees– please reach out to me (Brandon Tudor) on LinkedIn.When & Where Date: Thursday, February 27, 4:00 pm –...